LOBBYIST

Jeanne Haggerty

73ACTIVITIES

7ORGS REPRESENTED

4BILLS

Revolving door — covered positions

Federal positions Jeanne held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member

Organizations represented

Orgs whose LD-2 filings list Jeanne as an active lobbyist, sorted by activity volume.

Pharmaceutical Research and Manufacturers of America (PhRMA)20 activities Consumer Brands Association18 activities Pfizer12 activities AbbVie10 activities Bristol Myers Squibb8 activities California Life Sciences Association3 activities American Cancer Society Cancer Action Network, Inc.2 activities

Bills they file on

H.R. 14928 mentions

S. 8328 mentions

H.R. 8304 mentions

S. 8644 mentions

Topics in Filings

Policy topics Jeanne files on across all their LD-2 activities.

Pharmacy benefit manager reform×12

General education about policies×10

Impacting pharmaceutical development, approval and reimbursement×10

Rebates for Medicare Part D×8

Importation. 340B Program×8

Drug pricing×8

Prescription drug pricing issues, particularly related to MFN×6

Potential tariff actions under Section 232 of the Trade Act×6

IPI drug pricing proposal×4

Medicare Rebate Rule×4

Impacting Medicare Part D×4

Part B and 340 B programs×4

Show all 50 topics (+38 more) ▾

IP Protections related to trade agreements×4

Trade policies×4

Impacting pharmaceutical development×4

Legislative proposals related to WTO TRIPS Waiver×4

340B Reform×4

Drug pricing policies, implementation×4

ORPHAN Cures Act×4

HELP Copays Act×4

Pharmacy Benefit Manager transparency, including Lower Costs×4

More Transparency Act, monitoring efforts around direct-to-consumer policies×4

Drug pricing proposals×4

P.L. 119-21×4

Prescription drug advertising issues×2

Drug safety and drug counterfeiting×2

Drug importation×2

340B program×2

Proposals, issues×2

Tax issues×2

Affecting the pharmaceutical industry including international tax×2

Vaccine excise tax issues×2

Medicare payment issues×2

Medicare Part D×2

Protecting Seniors Through Immunization Act×2

Support for immunization access, access to migraine screening×2

Support for tick-borne disease research and womens health×2

One Big Beautiful Bill Act×2

General cancer care access, innovation and screening, including childhood cancer×1

NIH funding for Cancer Research×1

Medicare Multi-Cancer Early Detection Screening Coverage Act×1

FDA drug approval, importation×1

PBM reform×1

NIH funding, support and clinical trials×1

Monitor trade and tariff issues×1

Health care IP×1

Transitional coverage for innovative medical devices×1

IRA implementation×1

Oppose proposed changes to the Medicaid Drug Rebate Program×1

Medicare coverage for anti-obesity medication and multi-cancer screening tests×1

Issue mix

LDA general-issue codes weighted by activity count.

Medicare/Medicaid12

Health Issues12

Trade (domestic/foreign)10

Food Industry (safety, labeling, etc.)6

Beverage Industry6

Consumer Issues/Safety/Products6

Budget/Appropriations6

Defense6

Pharmacy6

Taxation/Internal Revenue Code3